Department of Obstetrics and Gynecology

Permanent URI for this community

https://hdl.handle.net/1805/6751

Browse

Browsing Department of Obstetrics and Gynecology by Author "Abbasi, Forough"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Expression of the BAD pathway is a marker of triple-negative status and poor outcome
    (Nature Research, 2019-11-25) Boac, Bernadette M.; Abbasi, Forough; Ismail-Khan, Roohi; Xiong, Yin; Siddique, Atif; Park, Hannah; Han, Mingda; Saeed-Vafa, Daryoush; Daryoush, Daryoush; Henry, Brendon; Pena, M. Juliana; McClung, E. Clair; Robertson, Sharon E.; Todd, Sarah L.; Lopez, Alex; Sun, Weihong; Apuri, Susmitha; Lancaster, Johnathan M.; Berglund, Anders E.; Magliocco, Anthony M.; Marchion, Douglas C.; Obstetrics and Gynecology, School of Medicine
    Triple-negative breast cancer (TNBC) has few therapeutic targets, making nonspecific chemotherapy the main treatment. Therapies enhancing cancer cell sensitivity to cytotoxic agents could significantly improve patient outcomes. A BCL2-associated agonist of cell death (BAD) pathway gene expression signature (BPGES) was derived using principal component analysis (PCA) and evaluated for associations with the TNBC phenotype and clinical outcomes. Immunohistochemistry was used to determine the relative expression levels of phospho-BAD isoforms in tumour samples. Cell survival assays evaluated the effects of BAD pathway inhibition on chemo-sensitivity. BPGES score was associated with TNBC status and overall survival (OS) in breast cancer samples of the Moffitt Total Cancer Care dataset and The Cancer Genome Atlas (TCGA). TNBC tumours were enriched for the expression of phospho-BAD isoforms. Further, the BPGES was associated with TNBC status in breast cancer cell lines of the Cancer Cell Line Encyclopedia (CCLE). Targeted inhibition of kinases known to phosphorylate BAD protein resulted in increased sensitivity to platinum agents in TNBC cell lines compared to non-TNBC cell lines. The BAD pathway is associated with triple-negative status and OS. TNBC tumours were enriched for the expression of phosphorylated BAD protein compared to non-TNBC tumours. These findings suggest that the BAD pathway it is an important determinant of TNBC clinical outcomes.